Valmark Advisers Inc. Acquires 955 Shares of Pfizer Inc. (NYSE:PFE)

Valmark Advisers Inc. boosted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 2.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 41,716 shares of the biopharmaceutical company’s stock after purchasing an additional 955 shares during the quarter. Valmark Advisers Inc.’s holdings in Pfizer were worth $1,107,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of PFE. L.M. Kohn & Company increased its holdings in Pfizer by 4.4% in the 4th quarter. L.M. Kohn & Company now owns 37,911 shares of the biopharmaceutical company’s stock valued at $1,006,000 after acquiring an additional 1,597 shares during the last quarter. Hourglass Capital LLC increased its holdings in Pfizer by 42.1% in the 4th quarter. Hourglass Capital LLC now owns 397,720 shares of the biopharmaceutical company’s stock valued at $10,552,000 after acquiring an additional 117,820 shares during the last quarter. Secured Retirement Advisors LLC bought a new stake in shares of Pfizer in the fourth quarter worth about $206,000. Strategic Financial Concepts LLC bought a new stake in shares of Pfizer in the fourth quarter worth about $2,281,000. Finally, Allworth Financial LP increased its holdings in shares of Pfizer by 12.9% in the fourth quarter. Allworth Financial LP now owns 132,932 shares of the biopharmaceutical company’s stock worth $3,458,000 after purchasing an additional 15,177 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Down 0.6 %

Shares of PFE opened at $25.50 on Tuesday. The firm has a fifty day moving average price of $26.28 and a 200-day moving average price of $27.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $144.48 billion, a P/E ratio of 18.08, a P/E/G ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. The business had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company’s revenue for the quarter was up 24.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.10 EPS. Equities research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 annualized dividend and a yield of 6.75%. This is a boost from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio is 121.99%.

Insider Buying and Selling

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of the company’s stock in a transaction on Thursday, February 13th. The shares were bought at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the acquisition, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.06% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. Evercore ISI raised Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. StockNews.com cut shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. Citigroup reduced their price target on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a report on Wednesday, October 23rd. Finally, UBS Group reduced their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a report on Wednesday, January 8th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.